Lifileucel Shows Feasibility in Metastatic Sarcomas
A pilot trial found the cell therapy was infusible in most patients with advanced liposarcoma or pleomorphic sarcoma, with an early efficacy signal.
Global Cancer News
Coverage here follows cancer as a subject of research and public health — treatment advances, drug approvals, clinical trial findings, screening guideline updates and the studies that describe risk and survivorship. Reporting draws on peer-reviewed science, regulatory proceedings and the policy debates around access and cost.
Recent news
November 8, 2026
WTX-124 Shows Activity in Solid TumorsA phase 1/1b study tested the tumor-activated IL-2 prodrug WTX-124 alone and with pembrolizumab in immune-sensitive solid tumors.
November 7, 2026
Bispecific Combo Shows Prostate Cancer ResponsesEarly phase 1 data for a two-drug regimen reported responses in men with metastatic castration-resistant prostate cancer.
November 7, 2026
Iksuda Plans IKS03 Lymphoma Data at ASHEarly phase 1 results show 53% objective response rate in advanced B-cell non-Hodgkin lymphoma, with updated data due at the 2026 ASH meeting.
November 7, 2026
Oncolytic Virus Shows 42% Response in Solid TumorsEarly STEALTH-001 trial data presented at the 2026 SITC Annual Meeting report responses in patients with advanced solid tumors treated with intratumoral VET3-TGI.
November 6, 2026
Immunocore Plans Phase II/III Uveal Melanoma TrialEarly results show a combination therapy with Kimmtrak and brenetafusp, with a randomised study planned for patients with advanced uveal melanoma.
November 6, 2026
Lichen Planus-Like Rash Masks Rare T-Cell LymphomaA case report describes a 61-year-old man whose persistent lesions were repeatedly misdiagnosed before lymphoma was identified.
November 6, 2026
Rilvegostomig Combo Shows Promise in Early Breast CancerA phase 2 trial found the immunotherapy and antibody-drug conjugate pairing active in high-risk HER2-negative early breast cancer.
November 6, 2026
Zipalertinib Combo Extends Lung Cancer SurvivalA Phase 3 trial found adding zipalertinib to chemotherapy nearly doubled progression-free survival in untreated EGFR exon 20 lung cancer.
November 6, 2026
Tumor Testing Reveals Hidden Inherited Cancer RisksGenetic analysis of tumors identifies hereditary cancer-predisposition variants that standard diagnostic pathways may miss.
November 6, 2026
Cesalatamig Shows 33% Response in Lung CancerOncoC4's Phase 1/2 pooled analysis reports early activity and tolerability of cesalatamig monotherapy in previously treated non-small cell lung cancer.
More in Cancer
The beat runs across clinical trial results, regulatory approvals for new therapies, screening recommendation changes, survivorship and quality-of-life research, and the environmental and genetic studies that expand understanding of risk. Immunotherapy and targeted therapy have restructured the treatment landscape enough to generate a sustained reporting track on which cancers respond to which approaches and what the evidence shows. Screening guideline changes attract broad public attention because they reach people who are not patients, making recommendations one of the most widely read categories of cancer coverage. Drug pricing in oncology has produced a parallel policy story, since the cost of approved therapies determines access and drives legislative and regulatory responses that extend beyond the clinical findings.